Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Rectal Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma 1

Interventions

Doxorubicin 20Cyclophosphamide 18Radiotherapy 17Ifosfamide 13Vincristine 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Biopsy 10Etoposide 9Filgrastim 8Dactinomycin 8X-Rays 6Temozolomide 6Sirolimus 6Phantoms, Imaging 6Melphalan 6temsirolimus 5cixutumumab 5Thalidomide 5Celecoxib 5Sorafenib 4Radiation 4Nuclear Medicine Department, Hospital 4Ipilimumab 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Carboplatin 4pazopanib 3ixabepilone 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma × Dasatinib × Clear all
NCT01643278 2017-01-10

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡